market performance

$DJT has crashed from $70.90 debut to under $9. Truth Social stalls at 6.3M users while analysts warn stock unlikely to outperform market.

Palantir trades at 87x price-to-sales, S&P 500's highest. Historical data shows only 21% of ultra-expensive stocks outperform annually.

Palantir trades at 80x sales—25x the S&P 500 average. History shows only 10% of companies at half this valuation beat the market over three years.

Coca-Cola's fortress brand and dividend growth appeal, but elevated 25.6 P/E valuation in a mature, slow-growth industry suggests limited five-year return potential.

Palantir surged 547% over five years but faces valuation scrutiny at 110x forward earnings. Strong Q4 growth and AI demand offer upside, though 26% recent pullback signals volatility ahead.

Take-Two's stock down 17% in 2026, lagging S&P 500 by significant margin. Grand Theft Auto VI's November launch expected to become major growth catalyst for company.

State Street forecasts small and mid-cap index funds will outperform the S&P 500 over five years, but critics highlight a structural flaw: these funds sell winners graduating to larger indexes while holding losers.

Vertex Pharmaceuticals needs 26% annual growth to turn $100K into $1M by 2036, but its maturing cystic fibrosis franchise and competitive pressures make this ambitious target unlikely despite solid fundamentals.